Boston Scientific Corporation $BSX Shares Bought by WD Rutherford LLC

WD Rutherford LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 53.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 35,040 shares of the medical equipment provider’s stock after acquiring an additional 12,191 shares during the quarter. WD Rutherford LLC’s holdings in Boston Scientific were worth $3,341,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of BSX. Brighton Jones LLC lifted its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the period. FWL Investment Management LLC purchased a new position in Boston Scientific during the second quarter worth $26,000. Main Street Financial Solutions LLC grew its position in shares of Boston Scientific by 35.3% in the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock valued at $812,000 after purchasing an additional 1,971 shares during the period. Ieq Capital LLC grew its position in shares of Boston Scientific by 97.0% in the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock valued at $13,275,000 after purchasing an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC grew its position in shares of Boston Scientific by 56.2% in the second quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after purchasing an additional 2,556 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX stock opened at $52.67 on Monday. Boston Scientific Corporation has a 12-month low of $52.52 and a 12-month high of $109.50. The firm has a market capitalization of $78.27 billion, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62. The business has a 50 day simple moving average of $63.40 and a 200 day simple moving average of $81.65. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Weiss Ratings cut Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday. Royal Bank Of Canada reduced their price objective on Boston Scientific from $105.00 to $100.00 and set an “outperform” rating on the stock in a research note on Thursday, April 23rd. Barclays dropped their target price on Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a research report on Thursday, April 23rd. Robert W. Baird dropped their target price on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a research report on Thursday, April 23rd. Finally, Evercore lowered their price objective on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $93.91.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.